On April 14, 2025, the FDA warned consumers and healthcare providers not to use counterfeit Ozempic (semaglutide) 1 mg injection that had entered the US drug supply chain after Novo Nordisk reported several hundred suspect units. The agency flagged risks of wrong active ingredient, incorrect dose, and contamination, and advised the supply chain to quarantine and verify the implicated lot. The alert sits atop a broader body of evidence - including pharmacovigilance analyses of suspected-counterfeit semaglutide where ~89% of reported adverse drug reactions were classified as serious (vomiting, nausea, hypoglycemia) - underscoring that the GLP-1 boom has spawned a parallel counterfeit and illicit-compounding safety problem.